))
Biotech’s Next Breakthrough Cycle: Dr. David Sans on Catalysts, Capital, and the Comeback of Innovation
Manage episode 514910418 series 3486351
Content provided by Water Tower Research. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Water Tower Research or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
In this episode of WTR Small-Cap Spotlight, Dr. David Sans, healthcare investment banker, former Novartis oncology researcher, and long-time biotech strategist, joins host Tim Gerdeman, Vice Chair, Co-Founder, and Chief Marketing Officer of Water Tower Research, for an in-depth discussion on the state of the biotech industry. Together, they explore why optimism is returning to the sector, which technologies and therapeutic categories are leading the rebound, and how investment and IPO trends are shaping the next phase of biotech growth. Discover the bullish underpinnings of The Wall Street Journal article last week titled “Why Biotech’s Rally Can Last This Time”.
167 episodes
Share
